Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor replacement therapy presented as an injectable solution for intravenous use. It is used to treat patients with Hemophilia B and other conditions involving factor IX deficiency.

GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Immunine is a recombinant factor IX product that restores the intrinsic pathway of the coagulation cascade in patients with factor IX deficiency.

Hemophilia B: provides the missing factor IX to enable normal clot formation and reduce bleeding episodes. Acquired factor IX deficiency: restores clotting ability in patients who have lost factor IX due to disease or surgery.

Immunine may be associated with adverse reactions following intravenous infusion.

Common Side Effects: - Infusion‑related reactions such as mild fever or chills - Headache or mild arthralgia - Nausea or mild gastrointestinal discomfort

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Development of neutralizing inhibitors (antibodies) against factor IX - Thrombotic events including deep‑vein thrombosis or pulmonary embolism

Before initiating therapy, clinicians should consider several safety measures.

Monitor for inhibitor development: assess antibody formation periodically. Assess bleeding risk: evaluate patient history of severe hemorrhage. Use aseptic technique: ensure sterile preparation and administration. Adjust dose in renal or hepatic impairment: consider organ function when dosing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Factor IX concentrates can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Concomitant anticoagulants (e.g., warfarin) may increase bleeding risk. - Use with activated prothrombin complex concentrates may predispose to thrombosis. - High‑dose immunoglobulins may reduce factor IX efficacy.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics may affect renal clearance of the product. - Live vaccines may have altered immune response when given concurrently. - Concurrent use of other clotting factor products requires careful monitoring of overall coagulation status.